Benzinga | May 24, 2021 07:32AM EDT

OPKO Health Reports Transfer Of Licensed Rights to RAYALDEE In Japan To Vifor

OPKO Health, Inc. (NASDAQ:OPK) today announced a transfer of the licensed rights to RAYALDEE(r) in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP).

On May 17, 2021, JT notified OPKO of its decision to terminate the exclusive agreement with OPKO's subsidiary, EirGen Pharma, Ltd., for the development and commercialization of RAYALDEE(r) in Japan based on a comprehensive review of its development pipeline.

Concurrently with the termination of JT's rights, EirGen and VFMCRP have agreed to transfer the rights to RAYALDEE(r) in Japan to VFMCRP by including Japan into the existing exclusive agreement between the two companies, executed on May 9, 2016, for the development and commercialization of RAYALDEE(r) in Europe and certain other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency.